Ingenium Therapeutics Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
16
- Latest Deal Type
-
Series B
- (In Progress)
- Latest Deal Amount
-
$4.12M
- Investors
-
7
Ingenium Therapeutics General Information
Description
Operator of a treatment development company intended to develop an anti-cancer immune therapy. The company uses NK cells, a type of immune cell that exists in the human body, for the treatment of intractable leukemia, enabling cancer patients with immuno-anticancer drugs that work most effectively in the immune environment.
Contact Information
Website
www.ingeniumcell.co.krCorporate Office
- 1662 Yuseong-daero, Yuseong-gu
- Number 406, Jeonmin-dong, Daejeon Bioventure Town
- Daejeon, Yuseong
- South Korea
Corporate Office
- 1662 Yuseong-daero, Yuseong-gu
- Number 406, Jeonmin-dong, Daejeon Bioventure Town
- Daejeon, Yuseong
- South Korea
Ingenium Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC (Series B) | 13-Feb-2026 | $4.12M | In Progress | Clinical Trials - General | ||
| 4. Early Stage VC (Series A) | 21-Nov-2023 | Completed | Clinical Trials - General | |||
| 3. Early Stage VC (Series A) | 01-Sep-2022 | Cancelled | Clinical Trials - General | |||
| 2. Early Stage VC | 01-Mar-2022 | $4.75M | $4.75M | Completed | Clinical Trials - General | |
| 1. Seed Round | 30-Apr-2021 | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Ingenium Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Ingenium Therapeutics Patents
Ingenium Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2022359191-A1 | Composition for enhancing activity of natural killer cells | Active | 05-Oct-2021 | ||
| AU-2022359191-B2 | Composition for enhancing activity of natural killer cells | Active | 05-Oct-2021 | ||
| EP-4413992-A1 | Composition for enhancing activity of natural killer cells | Pending | 05-Oct-2021 | ||
| EP-4413992-A4 | Composition for enhancing activity of natural killer cells | Pending | 05-Oct-2021 | ||
| US-20250230190-A1 | Composition for enhancing activity of natural killer cells | Pending | 05-Oct-2021 | C07K7/08 |
Ingenium Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Ingenium Therapeutics Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Daewoo Dang Healthcare | Corporation | Minority | ||
| Capstone Partners Korea | Venture Capital | Minority | ||
| Kairos Venture Partners | Venture Capital | Minority | ||
| KGROUND Ventures | Venture Capital | Minority | ||
| Laplace Partners | Venture Capital | Minority |
Ingenium Therapeutics FAQs
-
When was Ingenium Therapeutics founded?
Ingenium Therapeutics was founded in 2020.
-
Where is Ingenium Therapeutics headquartered?
Ingenium Therapeutics is headquartered in Daejeon, South Korea.
-
What is the size of Ingenium Therapeutics?
Ingenium Therapeutics has 16 total employees.
-
What industry is Ingenium Therapeutics in?
Ingenium Therapeutics’s primary industry is Biotechnology.
-
Is Ingenium Therapeutics a private or public company?
Ingenium Therapeutics is a Private company.
-
What is Ingenium Therapeutics’s current revenue?
The current revenue for Ingenium Therapeutics is .
-
How much funding has Ingenium Therapeutics raised over time?
Ingenium Therapeutics has raised $8.75M.
-
Who are Ingenium Therapeutics’s investors?
Daewoo Dang Healthcare, Capstone Partners Korea, Kairos Venture Partners, KGROUND Ventures, and Laplace Partners are 5 of 7 investors who have invested in Ingenium Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
